Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

Biotech reporting on November 6, 2026, highlighted new cardiovascular data linking Amgen's Repatha to fewer heart attacks compared to Zetia, with Repatha lowering heart attack risk by 20 percent beyond statin therapy. Concurrently, Novartis disclosed seven previously unreported tumor cases in pediatric patients receiving Zolgensma, bringing the total to nine tumor reports since the spinal muscular atrophy gene therapy was approved in 2019.

Repatha heart attack data

• ▪Amgen's Repatha demonstrated fewer heart attacks beyond statin therapy in cardiovascular data reported on November 6, 2026
• ▪Amgen's Repatha was linked to a 20 percent reduction in heart attack risk beyond statin therapy in reported biopharma data on November 6, 2026

Zolgensma pediatric tumor cases

• ▪Novartis has received nine total tumor reports in pediatric patients who received Zolgensma since the spinal muscular atrophy gene therapy was approved in 2019
• ▪Novartis disclosed seven previously unreported cases of tumors in children treated with Zolgensma, a gene therapy for spinal muscular atrophy, as reported on November 6, 2026